Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis
Sanyal AJ, Newsome PN, Kliers I, et al.
N Engl J Med. Pub. online 30 Apr 2025.
Leggi
AIFA: Monitoraggio della Spesa Farmaceutica Nazionale e Regionale Gennaio-Dicembre 2024
29/04/2025
Leggi
Insulin resistance in type 1 diabetes is a key modulator of platelet hyperreactivity
Sagar RC, Yates DM, Pearson SM, et al.
Diabetologia. Pub. online 30 Apr 2025.
Leggi
High-dose semaglutide (up to 16 mg) in people with type 2 diabetes and overweight or obesity: a randomized, placebo-controlled, phase 2 trial
Aroda VR, Jørgensen NB, Kumar B, et al.
Diabetes Care. 2025:dc242425.
Leggi
Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial
Knowler WC, Doherty L, Edelstein SL, et al.
Lancet Diabetes Endocrinol. Pub. online 28 Apr 2025.
Leggi
Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes
Lim CE, Pasternak B, Eliasson B, Ueda P
Diabetologia. Pub. online 2 May 2025.
Leggi
Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial
Sattar N, Neeland IJ, Dahlqvist Leinhard O, et al.
Lancet Diabetes Endocrinol. Pub. online 30 Apr 2025.
Leggi
SGLT2 inhibitors and risk for hyperkalemia among individuals receiving RAAS inhibitors
Wing S, Ray JG, Yau K, et al.
JAMA Intern Med. 2025:e250686.
Leggi
Mortality risk following ischaemic and non-ischaemic heart failure in people with type 2 diabetes: Observational study in England, 2000-2021
Panchal K, Lawson CA, Shabnam S, et al.
Diabetes Obes Metab. Pub. online 2 May 2025.
Leggi